One patient presented with multiple metastases to the subcutaneous tissue and bone that responded to <i>ALK</i> inhibitor alectinib therapy, and the tumor was observed to regress 10 months after the initial <i>ALK</i> inhibitor therapy. The gene discussed is ALK; the disease is neoplasm.